- Home
- Companies
- st kitts nevis
- biomarker development
Refine by
Biomarker Development Suppliers Serving St Kitts Nevis
47 companies found
Premium
based inFramingham, MASSACHUSETTS (USA)
SCIEX empowers you to solve the most impactful analytical challenges in quantitation and characterization in environmental testing. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field ...
based inRockville, MARYLAND (USA)
20/20 GeneSystems (“20/20”) is focused on on reducing cancer deaths worldwide through its years of experience in the development and use of cancer biomarker test development. By leveraging this expertise and combining it with advanced machine ...
based inNewark, CALIFORNIA (USA)
ACD - a Bio-Techne brand, shortens the path to personalized medicine and enables research, drug development and clinical applications by unlocking the power of RNA. ACD is a leader in the emerging field of molecular pathology, developing cell- and ...
There is growing interest in RNA-based biomarkers and measuring RNA expression holds great promise for stratifying patients based on drug response, drug efficacy and risk of side effects. RNAscope in situ hybridization enables molecular detection in ...
based inMarseille Cedex 9, FRANCE
Veracyte, formerly HalioDx, is a global diagnostics company that improves patient care by answering important clinical questions to inform diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. Our ...
Veracyte’s Cancer Immune Atlas allows clinical researchers to maximize the value of the data generated through our Immunogram analysis platform. The Cancer Immune Atlas creates a reference database from individual Immunograms, to generate ...
based inBangalore, INDIA
Cellworks’ mission is to serve patients through advances in personalized medicine that significantly improve treatment success. We achieve better outcomes by predicting a successful match between patients and drug therapies – their Therapy Response ...
Accelerate drug development timelines, reduce risks and lower costs. Our biosimulation platform predicts human clinical response to investigational drug candidates YEARS earlier than traditional development ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...
based inEschborn, GERMANY
When we looked at the decision making landscape in organizations and observed that the available technologies and models were helping make decisions but with fixed cycles of information processing, running in batches, with little flexibility and ...
Identify the biomarkers best suited for your needs: Diagnose rare or ambiguous diseases, Group patients by endotype response for prognosis, Assess disease etiology to determine responsive patient group ...
based inSeattle, WASHINGTON (USA)
Nexelis is your partner for assay and biomarker development, advanced bioanalytical and laboratory testing, and translational immunology. As the leading specialty laboratory, we have unrivaled expertise in immunology, specifically in the areas of ...
Testing Services to Support Your Preclinical and Phase I-IV Drug Programs. Nexelis, a Q² Solutions Company, provides biomarker assay services in inflammation and immunology, oncology, organ injury (renal), nutritional health, ...
based inBerlin, GERMANY
We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high ...
based inSeoul, SOUTH KOREA
We make software that transforms medical data into deeper insight. Our AI technology takes medical intelligence to the next level: data-driven medicine. We aim to solve the most critical issues in cancer care today: reduce medical cost and prolong ...
Predicting immunotherapy outcome with AI analysis; Finding more responders to cancer treatment; Tissue Data is huge and complex; Complex is what AI does ...
based inPak Shek Kok, HONG KONG
Artificial intelligence for every step of pharmaceutical research and development. Our mission is to accelerate drug discovery and drug development by continuously inventing and deploying new artificial intelligence technologies. We provide AI ...
based inNavi Mumbai, INDIA
Yashraj Biotech Limited manufactures a wide range of high pure biomarkers in the form of native and recombinant proteins that are used by the diagnostic industry as controls, calibrators and immunogens. YBL has been the preferred partner of most of ...
based inHuningue, FRANCE
FIRALIS is a biotechnology company located in the very heart of BioValley, on the true triple border of FR-DE-CH, only a few minutes walking distance to Basel, the pharmaceutical capital of Europe. Firalis creates novel values via biomarker ...
NEUROLINCS : A non-invasive in-vitro diagnostic test measuring 7494 brain-enriched long non-coding RNAs (lncRNAs) that are specific to neurodegenerative ...
based inSan Francisco, CALIFORNIA (USA)
Tempo Bioscience, Inc (Tempo) develops human stem cells (human iPSC technology) based cell models and biosensor enabling technologies for preclinical drug discovery & development, biobanking, in vitro diagnostics, and biomarker development. Our ...
based inRegensburg, GERMANY
numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs that could not be addressed by single biomarker-based ...
Cancer is among the leading causes of death worldwide. Approximately 38 % of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013 – 2015 data1). Cancer can occur in any organ and in any cell ...
based inDiepenbeek, BELGIUM
Founded in 2012, InnoSer is an innovative and dynamic contract research organization supporting preclinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug ...
We optimize your lead compounds using expertise and data-driven decisions. The lead optimization stage marks the end of the drug discovery phase and the start of pharmaceutical or biological development. Insight into the absorption, distribution, ...
based inSharnbrook, UNITED KINGDOM
AgPlus Diagnostics is proud to present the Agilis Reader. A portable diagnostic solution, comparable to any fixed laboratory analyzer, The Agilis Reader is a quantitative diagnostic reader that can be used in multiple market applications that when ...
We are proud to have developed a tried and tested B2B commercial approach. We strive to progress partnerships including technology licensing, assay development plus manufacture and supply, with collaborators in a variety of applications and business ...
based inNewton, MASSACHUSETTS (USA)
BioSensics is a global leader in development of wearable sensors and digital platforms for clinical trials, patient monitoring and health assessment. BioSensics was founded in 2007 by three scientists from Harvard University with a vision of ...
A transformative mobile health application for monitoring motor, speech and cognitive function, and mental ...
based inSeattle, WASHINGTON (USA)
Headquartered in Seattle, Avaden Biosciences operates the largest human biosample network in the world. Our U.S.-based partnerships with over 200 CLIA/CAP accredited facilities provide immediate access to more than 35,000,000 highly annotated ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell ...
